The management of anticoagulation therapy in patients undergoing elective procedures requires a precise understanding of both the risks associated with warfarin and the potential consequences of discontinuation. Current guidelines indicate that continuing warfarin prior to elective surgeries is not recommended for individuals taking the medication for stroke prevention, particularly those with atrial fibrillation. This recommendation is underscored by findings from the BRIDGE trial, which notably excluded patients who experienced an ischemic stroke within the preceding 12 weeks, focusing instead on those with more distant strokes.
For patients who fall into this latter category, the cessation of warfarin without bridging therapy using low-molecular-weight heparin or antiplatelet agents is suggested as the appropriate management strategy. This approach minimizes the risk of bleeding while also safeguarding against the potential for thromboembolic events. Importantly, there is currently no substantial evidence supporting the use of a lower target International Normalized Ratio (INR) as a protective measure during the perioperative period.
From a clinical perspective, this highlights the importance of individualizing preoperative management, taking into account both the patient’s thromboembolic risk and the nature of the planned procedure. For experts engaged in this area, understanding the balance of these factors is essential for optimizing patient outcomes and ensuring safe surgical practices.
Be the first to comment